866-997-4948(US-Canada Toll Free)

Pharmacogenomics Partnering Terms and Agreements

Published By :

Current Partnering

Published Date : Nov 2014

Category :

Biotechnology

No. of Pages : 455 Pages


The Pharmacogenomics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the pharmacogenomics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter pharmacogenomics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pharmacogenomics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 140 links to online copies of actual pharmacogenomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of pharmacogenomics dealmaking and business activities. 

Chapter 1 provides an introduction to the report, whilst 

Chapter 2 provides an overview of the trends in pharmacogenomics dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading pharmacogenomics deals since 2009. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top big pharma companies with a brief summary followed by a comprehensive listing of pharmacogenomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
 
Chapter 5 provides a comprehensive and detailed review of pharmacogenomics partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of pharmacogenomics partnering deals signed and announced since January 2009. The chapter is organized by specific pharmacogenomics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in pharmacogenomics partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of pharmacogenomics technologies and products.

Pharmacogenomics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to pharmacogenomics trends and structure of deals entered into by leading companies worldwide.

Pharmacogenomics Partnering Terms and Agreements includes:

  • Trends in pharmacogenomics dealmaking in the biopharma industry since 2009
  • Analysis of pharmacogenomics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life pharmacogenomics deals
  • Access to over 140 pharmacogenomics deal records and contract documents where available
  • The leading pharmacogenomics deals by value since 2009
  • Most active pharmacogenomics dealmakers since 2009
  • The leading pharmacogenomics partnering resources
 
In Pharmacogenomics Partnering Terms and Agreements, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Report scope

The Pharmacogenomics Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 140 pharmacogenomics deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise pharmacogenomisc rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Pharmacogenomics Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of pharmacogenomics deal trends since 2009
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of pharmacogenomics agreements with numerous real life case studies
  • Access to over 140 pharmacogenomics online deals entered into by the world’s biopharma companies
  • Detailed access to actual pharmacogenomics contracts enter into by the leading fifty bigpharma companies
  • Insight into the terms included in a pharmacogenomics agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Table of Content

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in pharmacogenomics dealmaking
2.1. Introduction
2.2. Pharmacogenomics partnering over the years
2.3. Big pharma pharmacogenomics dealmaking activity
2.4. Most active Pharmacogenomics dealmakers
2.5. Pharmacogenomics partnering by deal type
2.6. Pharmacogenomics partnering by disease type
2.7 Average deal terms for Pharmacogenomics
2.7.1 Pharmacogenomics headline values
2.7.2 Pharmacogenomics upfront payments
2.7.3 Pharmacogenomics milestone payments
2.7.4 Pharmacogenomics royalty rates

Chapter 3 – Big pharma pharmacogenomics deals
3.1. Introduction
3.2. How to use big pharma pharmacogenomics partnering deals
3.3. Big pharma pharmacogenomics partnering company profiles
Abbott
AstraZeneca
Bayer
Bristol-Myers Squibb
Eisai
Eli Lilly
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck & Co
Novartis
Pfizer
Roche
Takeda

Chapter 4 – Pharmacogenomics dealmaking directory
4.1. Introduction
4.2. Company A-Z
AB-Biotics
Abbott Laboratories
Abbott Molecular
Abyntek Biopharma
AEterna Zentaris
Affomix
Akonni Biosystems
Alere GmbH
Algeta
ALS Emergency Treatment Fund
American Society of Clinical Oncology (ASCO)
Antitope
Applied BioCode
Aptiv Solutions
Ariana Pharma
Array Biopharma
AssureRx Health
AstraZeneca
Astrimmune
Asuragen
AutoGenomics
Aviir Diagnostics
Bayer
Bayer Vital
Beckman Coulter
Beijing Health Bureau
BioBay
Biomatrica
BioMerieux
BioReference Laboratories
Boulder Diagnostics
Bristol-Myers Squibb
Caliper Life Sciences
Cancer Genetics
CancerGuide Diagnostics
Caris Life Sciences
Case Western Reserve University
Catholic Health Initiatives
Celera
Cephalon
Cernostics
Champions Oncology
ChanTest
CHDI Foundation
Clarient
Clinical Data
CollabRx
CombiMatrix
Companion Dx Reference Lab
CompanionDx Reference Lab
Complete Genomics
CPGR
Cylene Pharma
Dana-Farber Cancer Institute
DARA BioSciences
Definiens
Denovo Biopharma
Deutsches Herzzentrum
DiagnoCure
Diagnostic Hybrids
DNA Genotek
Duke University
DxS
Eisai
Eli Lilly
Empire Genomics
Enable Healthcare
EraGen Biosciences
Erytech
Essential Molecular Testing
Exact Sciences
Falco
Florida Hospital
Food and Drug Administration (FDA)
Foundation Medicine
Fox Chase Cancer Center
Genetic Technologies
Genome Diagnostics
Gentris
German Cancer Research Center
Gilead Sciences
GlaxoSmithKline
Golden Helix
Government of Germany
H3 Biomedicine
Health Discovery
HealthCore
Helmholtz Institute in Saarbrucken
HistoRx
Horizon Discovery
Hospices Civils de Lyon
Hospital for Special Surgery
Icon
ImaginAb
Inova Health System
Institut Pasteur
Invenshure
JDRF
Johns Hopkins University
Johnson & Johnson
KeyMarker
KINAXO Biotechnologies
KSB Diagnostics
Lab21
Laboratory Corporation of America
Leica Microsystems
London Genetics
Luminex
Lumiphore
Massachusetts General Hospital
Mayo Clinic
MD Anderson Cancer Center
MDxHealth
Medco Health Solutions
Medco Research Institute
Medical University South Carolina
Medinnova
Memorial Sloan Kettering Cancer Center
Merck and Co
Metamark Genetics
Minerva Biotechnologies
Molecular Devices
MolecularMD
Montreal Heart Institute
Morphisto
MP Biomedicals
Multimmune
MultiPlan
Myriad Genetics
Nanosphere
National Research Council Canada
National Science Foundation
Neogenomics
New York University
Novartis
On-Q-ity
Oncodesign
OncoMethylome
Oneome
OPKO Health
OvaGene Oncology
PDI
Pfizer
PGxHealth
PGXL Partners
PGXL Technologies
Pikamab
Population Genetics Technologies
Predictive Biomarker Sciences
Prometheus Laboratories
Pronto Diagnostics
PROOF Centre of Excellence for Commercialization and Research
Qiagen
QIAGEN (Suzhou) Translational Medicine Center
Qualcomm
Quest Diagnostics
Quintiles
Research Institute of the Hospital Universitari Vall d'Hebron
Response Genetics
Roche Diagnostics
Rules-Based Medicine
Russian Nanotechnology Corporation
Rx Review Service
Sage Bionetworks
SAIC-Frederick
Saladax Biomedical
Sanford Burnham Institute
Scripps Health
Scripps Translational Science Institute
Seegene
Shanghai Centers for Disease Control and Prevention
Shanghai Institutes of Preventative Medicine
Signal Genetics
SimuGen
Sinovac Biotech
Sirius Genomics
Sirius Laboratories
Smart Personalized Medicine
Source Bioscience
Spartan Bioscience
Stone Ridge Technology
SuperNova Diagnostics
SureGene
Takeda Pharmaceutical
Targazyme
Tarrot
TcLand Expression
TGen Drug Development
The Biomarker Factory
Transgene
Transgenomic
UAB Research Foundation
Unibioscreen
United Kingdom Critical Care Genomics
University Gottingen
University of Bergen
University of California San Francisco
University of Montreal Pharmacogenomics Centre
University of Pittsburgh
University of Wurzburg
Vermillion
XDx
Yale University
Zinfandel Pharmaceuticals
4.3. By deal type
Asset purchase
Co-development
Collaborative R&D
Contract service
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Spin out
Supply
4.4. By therapy area
Cardiovascular
Central nervous system
Dermatology
Gastrointestinal
Genetic disorders
Hematology
Hospital care
Immunology
Infectives
Metabolic
Musculoskeletal
Oncology
Pediatrics
Psychiatry
Public health
Respiratory

Chapter 5 –Pharmacogenomics dealmaking by technology type
5.1. Introduction
5.2. Deals by pharmacogenomics type
Pharmacogenomics

Chapter 6 – Pharmacogenomics partnering resource center
6.1. Online pharmacogenomics partnering
6.2. Pharmacogenomics partnering events
6.3. Further reading on pharmacogenomics dealmaking

Appendices
Appendix 1 – Deal type definitions
Appendix 2 – Example pharmacogenomics partnering agreement
About Wildwood Ventures

Current Partnering
Current Agreements
Order Form – Upgrades to subscription access products
Recent titles from Current Partnering
Order Form – Reports

List of Chart


Figure 1: Pharmacogenomics partnering since 2009
Figure 2: Big pharma – top 50 – pharmacogenomics deals 2009 to 2014
Figure 3: Big pharma Pharmacogenomics deal frequency – 2009 to 2014
Figure 4: Active pharmacogenomics dealmaking activity– 2009 to 2014
Figure 5: Pharmacogenomics partnering by deal type since 2009
Figure 6: Pharmacogenomics partnering by disease type since 2009
Figure 7: Pharmacogenomics deals with a headline value by year- 2014
Figure 8: Pharmacogenomics deals with a headline value by year- 2013
Figure 9: Pharmacogenomics deals with a headline value by year- 2012
Figure 10: Pharmacogenomics deals with a headline value by year- 2011
Figure 11: Pharmacogenomics deals with a headline value by year- 2010
Figure 12: Pharmacogenomics deals with a headline value by year- 2009
Figure 13: Pharmacogenomics deals with an upfront value by year- 2014
Figure 14: Pharmacogenomics deals with an upfront value by year- 2013
Figure 15: Pharmacogenomics deals with an upfront value by year- 2012
Figure 16: Pharmacogenomics deals with an upfront value by year- 2011
Figure 17: Pharmacogenomics deals with an upfront value by year- 2010
Figure 18: Pharmacogenomics deals with an upfront value by year- 2009
Figure 19: Pharmacogenomics deals with a milestone value by year- 2014
Figure 20: Pharmacogenomics deals with a milestone value by year- 2013
Figure 21: Pharmacogenomics deals with a milestone value by year- 2012
Figure 22: Pharmacogenomics deals with a milestone value by year- 2011
Figure 23: Pharmacogenomics deals with a milestone value by year- 2010
Figure 24: Pharmacogenomics deals with a milestone value by year- 2009
Figure 25: Pharmacogenomics deals with a royalty rate by year- 2014
Figure 26: Pharmacogenomics deals with a royalty ratvalue by year- 2013
Figure 27: Pharmacogenomics deals with a royalty rate by year- 2012
Figure 28: Pharmacogenomics deals with a royalty rate by year- 2011
Figure 29: Pharmacogenomics deals with a royalty rate by year- 2010
Figure 30: Pharmacogenomics deals with a royalty rate value by year- 2009
Figure 31: Online partnering resources
Figure 32: Forthcoming partnering events
Figure 33: Deal type definitions
Figure 34: Pharmacogenomics partnering agreement between GlaxoSmithKline and Response Genetics, May 2010

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *